Novartis appoints global head of development

Promotes Timothy Wright to the role

Novartis has promoted Timothy Wright to global head, development of its Novartis Pharmaceuticals division.

Dr Wright joined the Swiss pharmaceutical firm in 2004 and most recently served as senior vice president and global head of translational sciences at Novartis Institutes for BioMedical Research (NIBR). His group included translational medicine, biomarker development, preclinical safety (toxicology), and drug metabolism and pharmacokinetics.

Previously, he worked for Pfizer Global Research and Development as the exploratory therapy area leader for inflammation. He also served as chief of the division of rheumatology and clinical immunology and as an endowed professor at the University of Pittsburgh.

Dr Wright has a biology degree from the University of Delaware and a medical degree from the Johns Hopkins University School of Medicine.

You may also like

Finance

Calypso enters into agreement to be acquired by Novartis

The acquisition of Calypso gives Novartis full rights to CALY-002, a pipeline-in-a-drug with potential in dermatology, gastrointestinal and rheumatology indications
Research & Development

Intellegens secures $2m to support research of oligonucleotide therapeutic manufacture

In collaboration with CPI, Intellegens has secured a grant from Innovate UK to fund a two year project to augment technology that will assist productivity and yields of oligonucleotide therapeutic manufacture
Manufacturing

Novartis completes acquisition of precision medicine developer Chinook

Novartis has announced the acquisition of a US-based biopharmaceutical company focused on the discovery of precision medicines for kidney diseases named Chinook Therapeutics
Manufacturing

Sterling Pharma Solutions acquires Novartis Facility in Ireland

The announcement follows several investments in the CDMO’s manufacturing capabilities in 2021, as well as acquisitions in the US and UK
Manufacturing

Novartis to revamp manufacturing with the help of Amazon

The retail giant outlines its plan to help Novartis build on real-time data to boost supply chain and overall operations
Finance

Lonza to buy sterile drug product fill-finish facility from Novartis

Swiss CDMO bids to keep management and operations teams and manufacture for Novartis at the site in Stein
Research & Development

Blackstone and Novartis: Joint venture targets cardiovascular disease

Anthos Therapeutics enters the market with US$250 million backing from Blackstone and an anti-thrombotic licensed from Novartis
Subscribe now